The very positive Vyvgart ADHERE data in chronic inflammatory demyelinating polyneuropathy, the recent approval for the subcutaneous version for generalized myasthenia gravis and the drug's already strong sales mean that Argenx will again be at the top of the M&A targets tree.
argenx N.V.'s position as one of the crown jewels of the European biotech sector, and a rumored takeover target for big pharma, has been enhanced by positive late-stage data on its pipeline-in-a-product Vyvgart in chronic inflammatory demyelinating polyneuropathy (CIDP).
The Belgian-Dutch group has unveiled topline results from the Phase III ADHERE study evaluating the subcutaneous version of the drug,...
Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.
Comes Days After PDUFA Pushback For GSK's Blenrep.
Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.
Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.
After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.
Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.
Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.
